Clinical Trials Browser

NCT05704634 2026-04-15

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Phase 1 Active not recruiting

56 enrolled

Thoracic

Lung Neoplasms

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Phase 1 Recruiting

127 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06508463 2026-04-13

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Phase 1 Recruiting

21 enrolled

Lymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT05064085 2026-04-06

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Phase 1 Completed

13 enrolled

Breast

Breast Neoplasms

NCT04722523 2026-03-30

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Phase 1 Recruiting

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms

NCT06826768 2026-03-04

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Phase 1 Recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 1 Not yet recruiting

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06902376 2025-11-05

NEO-COMBATXL

Phase 1 Recruiting

12 enrolled

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04826393 2025-10-22

ASP8374 + Cemiplimab in Recurrent Glioma

Phase 1 Completed

14 enrolled

CNSLymphoid

Glioblastoma, Glioma, Lymphoma, Follicular

NCT04428671 2025-08-14

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Phase 1 Recruiting

20 enrolled

Metastatic Skin Squamous Cell Carcinoma

NCT03477864 2025-04-29

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT04729725 2023-08-14

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Phase 1 Terminated

3 enrolled

Tumor-Agnostic

Neoplasm Metastasis